Currently, the first-generation somatostatin receptor ligands (fg-SRLs), octreotide LAR and
lanreotide autogel, are the mainstays of acromegaly treatment and achieve biochemical …

Transsphenoidal surgery is the first-line treatment for acromegaly. However, several factors
can modify surgical remission rates, such as the initial hormone levels, the size and …

Introduction Usually benign, pituitary tumors (PT) can be invasive and aggressive with a
propensity to progress and/or recur. Trouillas's clinicopathological classification attempts to …

Acromegaly results from growth hormone hypersecretion, predominantly caused by a
somatotroph pituitary neuroendocrine tumor (PitNET). Acromegaly-causing tumors are …

Simple Summary Pituitary neuroendocrine tumors (PitNET) are characterized to present a
heterogeneous behavior, and growth hormone (GH)-secreting PitNET is not an exception …

Extra-axial brain tumours are extra-cerebral tumours and are usually benign. The choice of
treatment for extra-axial tumours is often dependent on the growth of the tumour and …

Background and Aims Predictors of first-generation somatostatin receptor ligands (fgSRLs)
response in acromegaly have been studied for over 30 years, but they are still not …

High-risk pituitary adenomas are aggressive. They show clinical and imaging features
similar to those of carcinomas, including infiltration of the surrounding brain structures, but …

Introduction Sparsely granulated somatotroph adenoma/tumor (SGST) is thought to be more
clinically aggressive than densely granulated somatotroph adenoma/tumor (DGST) …

Growth Hormone-secreting adenomas exhibits variable biological behavior and
heterogeneous natural history, ranging from small adenomas and mild disease, to invasive …